Vaxcyte
Presence
Vaxcyte is one of the...
Vaxcyte is a company listed under the stock ticker PCVX (US).
Executives
View the org chart displaying its 22 main executives
Most searched biographies at Vaxcyte
- Grant Pickering, President, Chief Executive Officer and Director
- Heath Lukatch, Director
- Peter Hirth, Director
Popular executive movements at Vaxcyte
- Whitney Jones has joined the company as Chief People Officer (posted on January 17 2024).
- Jacks Lee has joined the company as Director (posted on November 29 2023).
Create your alert
to follow the executive moves at Vaxcyte.
Biotechnology
Vaxcyte has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Vaxcyte
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference - Vaxcyte, Inc.
- Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 - Vaxcyte, Inc.
- Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Vaxcyte, Inc.
- Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants - Vaxcyte, Inc.
- Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.
- Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference - Vaxcyte, Inc.
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants - Vaxcyte, Inc.
- Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older - Vaxcyte, Inc.
- Vaxcyte Announces Pricing of $750 Million Public Offering - Vaxcyte, Inc.
- Vaxcyte Appoints Whitney Jones as Chief People Officer - Vaxcyte, Inc.
- View more press releases Close
Social media about Vaxcyte
- Vaxcyte on Wikipedia, Google News & Yahoo Finance
- Vaxcyte on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Halley Gilbert 
